Avalo Therapeutics, Inc. short interest in 2021
In 2021, Avalo Therapeutics, Inc.'s disclosed short interest ran from 2.52% of shares outstanding on 15 Jan 2021 to 1.38% on 31 Dec 2021, a change of -1.14 percentage points. The year's high was 3.23% on 15 Oct 2021 and its low 1.38% on 31 Dec 2021, averaging 2.28% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.12 days on 29 Oct 2021. Full history: Avalo Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 2.52% (15 Jan 2021)
- End of year
- 1.38% (31 Dec 2021)
- Change
- -1.14 pp
- High
- 3.23% (15 Oct 2021)
- Low
- 1.38% (31 Dec 2021)
- Average
- 2.28%
- Highest days to cover
- 9.12 (29 Oct 2021)
- SEC filings marked
- 9
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 2.52% | 1.14 | results (8-K) |
| 29 Jan 2021 | 2.49% | 1.26 | |
| 12 Feb 2021 | 2.56% | 2.32 | |
| 26 Feb 2021 | 1.96% | 1.67 | |
| 15 Mar 2021 | 1.87% | 2.58 | 10-K filed, results (8-K) |
| 31 Mar 2021 | 1.93% | 4.94 | |
| 15 Apr 2021 | 1.89% | 3.25 | |
| 30 Apr 2021 | 2.58% | 3.57 | |
| 14 May 2021 | 2.71% | 1.00 | 10-Q filed, results (8-K) |
| 28 May 2021 | 2.54% | 2.48 | |
| 15 Jun 2021 | 2.25% | 2.09 | |
| 30 Jun 2021 | 2.69% | 3.20 | |
| 15 Jul 2021 | 2.60% | 7.30 | |
| 30 Jul 2021 | 2.43% | 3.13 | |
| 13 Aug 2021 | 2.49% | 5.55 | 10-Q filed, results (8-K) |
| 15 Oct 2021 | 3.23% | 6.23 | |
| 29 Oct 2021 | 3.08% | 9.12 | |
| 15 Nov 2021 | 1.67% | 6.77 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 1.58% | 5.63 | |
| 15 Dec 2021 | 1.47% | 5.33 | |
| 31 Dec 2021 | 1.38% | 3.71 |
See also: Avalo Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.